Acetyl triethyl citrate (ATEC) is a synthetic compound derived from citric acid. It is commonly used as a plasticizer, solvent, and fragrance ingredient. ATEC is synthesized through a reaction between citric acid and ethanol, followed by acetylation. ATEC is a colorless, viscous liquid with a mild citrus odor. It is considered a safe and effective plasticizer, imparting flexibility and durability to polymers. It is also used as a solvent in various applications, including inks, paints, and coatings. ATEC has been studied for its potential applications in various fields, including medicine, agriculture, and cosmetics. It exhibits potential antimicrobial properties and has been investigated for its role in promoting wound healing. Moreover, ATEC's biocompatibility and non-toxicity make it a promising candidate for use in drug delivery systems and biodegradable materials.'
acetyl triethyl citrate: structure in first source
ID Source | ID |
---|---|
PubMed CID | 6504 |
CHEMBL ID | 2105928 |
SCHEMBL ID | 42702 |
MeSH ID | M0449295 |
Synonym |
---|
LS-14339 |
citroflex a 2 |
triethyl acetylcitrate |
triethyl citrate acetate |
nsc-3887 |
citric acid, acetyl triethyl ester |
nsc3887 |
77-89-4 |
acetyl triethyl citrate |
tricarballylic acid, .beta.-acetoxytributyl ester |
citroflex a-2 |
1,3-propanetricarboxylic acid, 2-(acetyloxy)-, triethyl ester |
triethyl 2-acetoxy-1,3-propanetricarboxylate |
wln: 2ov1xvo2&ov1&1vo2 |
atec |
o-acetylcitric acid triethyl ester |
1,2,3-propanetricarboxylic acid, 2-(acetyloxy)-, triethyl ester |
2-(acetyloxy)-1,2,3-propanetricarboxylic acid, triethyl ester |
citric acid, triethyl ester, acetate |
brn 1804947 |
triethyl o-acetylcitrate |
triethyl 2-acetoxy-1,2,3-propanetricarboxylate |
nsc 3887 |
triethylester kyseliny acetylcitronove [czech] |
tricarballylic acid, beta-acetoxytributyl ester |
triethyl citrate, acetate |
ai3-03574 |
einecs 201-066-5 |
triethyl 2-acetylcitrate, 99% |
A0086 |
triethyl 2-acetyloxypropane-1,2,3-tricarboxylate |
triethyl 2-acetylcitrate |
FT-0659670 |
triethyl acetyl citrate |
acetyltriethyl citrate [nf] |
acetyltriethyl citrate |
triethylester kyseliny acetylcitronove |
1,2,3-propanetricarboxylic acid, 2-(acetyloxy)-, 1,2,3-triethyl ester |
unii-5wbr36t90e |
3-03-00-01105 (beilstein handbook reference) |
5wbr36t90e , |
cas-77-89-4 |
NCGC00256002-01 |
tox21_301483 |
dtxsid5044576 , |
dtxcid3024576 |
CHEMBL2105928 |
FT-0631334 |
acetyltriethyl citrate [usp-rs] |
acetyl triethyl citrate [inci] |
acetyltriethyl citrate [mart.] |
triethyl 2-acetoxypropane-1,2,3-tricarboxylate |
citric acid, o-acetyltriethyl ester |
SCHEMBL42702 |
AKOS024464792 |
uniplex 82 |
WEAPVABOECTMGR-UHFFFAOYSA-N |
1,2,3-propanetricarboxylic acid, 2-acetoxy-, triethyl ester |
triethyl 2-(acetyloxy)-1,2,3-propanetricarboxylate # |
mfcd00049378 |
SR-01000944782-1 |
sr-01000944782 |
acetyltriethyl citrate, united states pharmacopeia (usp) reference standard |
triethyl 2-acetylcitrate, pharmaceutical secondary standard; certified reference material |
E75747 |
ethchlorvynolciv(0.7ml) |
Q27262956 |
CS-W009904 |
Excerpt | Reference | Relevance |
---|---|---|
" Dermal application was not toxic in rabbits." | ( Final report on the safety assessment of acetyl triethyl citrate, acetyl tributyl citrate, acetyl trihexyl citrate, and acetyl trioctyl citrate. Johnson, W, 2002) | 0.58 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 51.5202 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 24.3365 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 12.3028 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (12.50) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 4 (50.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.47) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (12.50%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |